Table 2 Patient demographics and baseline characteristics.
| Â | Non-EBRT (n= 49) | EBRT (n= 35) | P-value |
|---|---|---|---|
Sex, n (%) | Â | Â | 0.308 |
   Male | 32 (65.3%) | 19 (54.3%) |  |
   Female | 17 (34.7%) | 16 (45.7%) |  |
Age, n (%) | Â | Â | 0.631 |
   ≤60 years old | 25(51.0%) | 16 (45.7%) |  |
   >60 years old | 24(49.0%) | 19 (64.3%) |  |
Clinical symptoms, n (%) | Â | Â | 0.386 |
   Asymptomatic | 9(18.4%) | 4 (11.4%) |  |
   Symptomatic | 40(81.6%) | 31 (88.6%) |  |
Diameter, mean ± SE (cm) | 8.6 ± 3.4 | 7.7 ±3.2 | 0.238 |
   ≤5, n (%) | 6(12.2%) | 7 (20.0%) | 0.280 |
   5-10, n (%) | 21 (44.9%) | 18 (51.4%) |  |
   ≥10, n (%) | 22 (44.9%) | 10 (28.6%) |  |
Intrahepatic lesions, n (%) | Â | Â | 0.898 |
   Solitary | 37(75.5%) | 26 (74.3%) |  |
   Multiple nodules | 12 (24.5%) | 9 (25.7%) |  |
Tumor Types, n (%) | Â | Â | 0.722 |
   Peripheral ICC | 34 (69.4%) | 23 (65.7%) |  |
   Central ICC | 15 (30.6%) | 12 (34.3%) |  |
Synchronous LN metastases, n (%) | Â | Â | 0.064 |
   No | 18 (36.7%) | 20 (57.1%) |  |
   Yes | 31 (63.3%) | 15 (42.9%) |  |
CA19-9, U/mL | Â | Â | 0.676 |
   ≤37, n (%) | 9 (18.4%) | 4 (11.4%) |  |
   37-600, n (%) | 15 (30.6%) | 11 (31.4%) |  |
   ≥600, n (%) | 25 (51.0%) | 20 (57.1%) |  |
TACE, n (%) | Â | Â | 0.118 |
   Yes | 13(26.5%) | 15(42.9%) |  |
   No | 36(73.5%) | 20(57.1%) |  |
TNM stage, n (%) | Â | Â | 0.175 |
   I |  | 1(2.9%) |  |
   II | 6(12.2%) | 8(22.9%) |  |
   III | 10(20.4%), | 9(25.7%) |  |
   IVA | 29(59.2%) | 12(34.3%) |  |
   IVB | 4(8.2%) | 5(14.3%) |  |